Vir Biotechnology (NasdaqGS:VIR) announced a global collaboration with Astellas Pharma to develop and commercialize VIR-5500 for metastatic castration-resistant prostate cancer. The agreement includes ...
DENVER -- The two-drug combination of doravirine and islatravir was as efficacious as the three-drug regimen of bictegravir, ...
After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...
The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...
Richter transformation develops in 2%–10% of CLL cases, often with rapid clinical decline, limited chemotherapy efficacy, and ...
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best cancer stocks to invest in now. On February 26, Revolution Medicines, Inc. (NASDAQ:RVMD) CEO Mark A. Goldsmith reiterated that the company ...
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results